Nanogel-based nasal vaccines for infectious and lifestyle-related diseases

Tatsuhiko Azegami; Yoshikazu Yuki; Rika Nakahashi; Hiroshi Itoh; Hiroshi Kiyono

doi:10.1016/j.molimm.2017.10.022

Nanogel-based nasal vaccines for infectious and lifestyle-related diseases

Mol Immunol. 2018 Jun:98:19-24. doi: 10.1016/j.molimm.2017.10.022. Epub 2017 Oct 31.

Authors

Tatsuhiko Azegami¹, Yoshikazu Yuki², Rika Nakahashi², Hiroshi Itoh³, Hiroshi Kiyono⁴

Affiliations

¹ Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan; Division of Mucosal Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan; International Research and Development Center for Mucosal Vaccines, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan.
² Division of Mucosal Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan; International Research and Development Center for Mucosal Vaccines, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan.
³ Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
⁴ Division of Mucosal Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan; International Research and Development Center for Mucosal Vaccines, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan; Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan. Electronic address: kiyono@ims.u-tokyo.ac.jp.

PMID: 29096936
DOI: 10.1016/j.molimm.2017.10.022

Abstract

Because the mucosa is the major entry route for most pathogens, the development of mucosal vaccines is a rational approach for protecting against these undesired agents. Mucosal administration of vaccine antigen is useful for non-infectious chronic diseases as well, because of its advantages over injection routes, including comparable efficacy in the induction of systemic immune responses, less pain, and no risk of adverse events at the injection site. However, because it is difficult to effectively induce and regulate antigen-specific mucosal and systemic immune responses when antigen alone is mucosally administered, an appropriate form of mucosal delivery vehicle must be used. Antigen delivery systems involving nanogels, which act as artificial chaperones and mucosal adhesives, are a promising approach to overcoming this problem. Here, we introduce current perspectives regarding the development of nanogel-based nasal vaccines for both infectious and lifestyle-related diseases.

Keywords: Hypertension; Nanogel; Nasal vaccine; Obesity; Pneumonia.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Antigens / administration & dosage
Botulism / immunology
Botulism / prevention & control
Chronic Disease
Clostridium botulinum / immunology
Communicable Diseases / immunology*
Communicable Diseases / therapy*
Drug Delivery Systems
Gels
Humans
Hypertension / immunology
Hypertension / therapy
Life Style*
Nanostructures / administration & dosage
Nasal Mucosa / immunology*
Obesity / immunology
Obesity / therapy
Pneumococcal Vaccines / administration & dosage
Vaccines / administration & dosage*

Substances

Antigens
Gels
Pneumococcal Vaccines
Vaccines